Navegando por Palavras-chave "biomarcadores"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosO comportamento de biomarcadores em dois esquemas terapêuticos hipolipemiantes(Universidade Federal de São Paulo (UNIFESP), 2014-06-02) Ferreira, Carlos Eduardo dos Santos [UNIFESP]; Fonseca, Francisco Antonio Helfenstein Fonseca [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)A progressão da aterosclerose tem sido associada com a ocorrência de desfechos cardiovasculares. Por outro lado, o tratamento antilipemiante tem sido relacionado com a não progressão ou mesmo involução da aterosclerose. A redução dos desfechos cardiovasculares é atribuída não somente à redução dos níveis de LDL colesterol (LDL-C), mas também aos efeitos pleiotrópicos das estatinas. Objetivos:neste trabalho foram comparadas duas formas de intervenção antilipemiante de similar eficácia na redução do LDL-C, mensurando os biomarcadores que auxiliam na avaliação do processo fisiopatológico da aterosclerose e da doença cardiovascular. Também foram examinados os efeitos no desenvolvimento anatômico da aterosclerose em carótidas nos dois grupos de pacientes. Métodos: pacientes com aterosclerose (n=75) foram aleatoriamente tratados com atorvastatina 80 mg ou associação ezetimiba 10 mg + atorvastatina 20 mg. A espessura íntima-média carotídea (EIMC) foi estimada no período basal para inclusão dos pacientes e ao final do tratamento com terapia antilipemiante por meio de ultrassom bi-dimensional. Correlações entre as variáveis mencionadas e fatores de risco tradicionais foram analisadas bem como a influência dos tratamentos antilipemiantes. Foi avaliado o comportamento de biomarcadores mais recentemente relacionados com a doença cardiovascular. Resultados: elevação de Mieloperoxidade (p<0,0001) e redução na EIMC (p<0,0001) em ambos os grupos. Redução de Apolipoproteína B e LDL pequena e densa (p = 0,005 e p=0,006) e elevação no NT-proBNP e nas micropartículas plaquetárias (p=0,04 e p=0,001) apenas no grupo da atorvastatina 80 mg. Elevação de micropartículas endoteliais apenas no grupo da associação (p=0,03). Conclusões: o estudo concluiu que de maneira geral os biomarcadores se comportaram de maneira similar nos dois diferentes esquemas terapêuticos, apenas com pequenas diferenças em alguns deles.
- ItemAcesso aberto (Open Access)Diffusion tensor imaging of brain white matter in Huntington gene mutation individuals(Assoc Arquivos Neuro- Psiquiatria, 2017) Saba, Roberta Arb [UNIFESP]; Yared, James H. [UNIFESP]; Doring, Thomas M. [UNIFESP]; Phys, Med [UNIFESP]; Borges, Vanderci [UNIFESP]; Ferraz, Henrique Ballalai [UNIFESP]Objective: To evaluate the role of the involvement of white matter tracts in huntingtin gene mutation patients as a potential biomarker of the progression of the disease. Methods: We evaluated 34 participants (11 symptomatic huntingtin gene mutation, 12 presymptomatic huntingtin gene mutation, and 11 controls). We performed brain magnetic resonance imaging to assess white matter integrity using diffusion tensor imaging, with measurement of fractional anisotropy. Results: We observed a significant decrease of fractional anisotropy in the cortical spinal tracts, corona radiate, corpus callosum, external capsule, thalamic radiations, superior and inferior longitudinal fasciculus, and inferior frontal-occipital fasciculus in the Huntington disease group compared to the control and presymptomatic groups. Reduction of fractional anisotropy is indicative of a degenerative process and axonal loss. There was no statistically significant difference between the presymptomatic and control groups. Conclusion: White matter integrity is affected in huntingtin gene mutation symptomatic individuals, but other studies with larger samples are required to assess its usefulness in the progression of the neurodegenerative process.
- ItemSomente MetadadadosImunoexpressão dos biomarcadores ts, cox-2, egfr, msh6, mlh1 no adenocarcinoma colorretal e sua correlação com o grau de diferenciação tumoral e os fatores prognósticos(Universidade Federal de São Paulo (UNIFESP), 2013-09-25) Batista, Wilson Roberto [UNIFESP]; Matos, Delcio Matos [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Objective: To study the immunoexpression of biomarkers TS, p53, COX2, EGFR, MSH6, MLH1 in patients with colorectal carcinoma, correlating with the degree of tumor differentiation and clinical prognostic factors patolólogicos. Methods: We analyzed tissues fixed in formalin and embedded in paraffin blocks of tumors from 107 patients, for immunohistochemistry by the streptavidin-biotin method using the technique of matrix arrangement of tissue samples (tissue-microarray). In the evaluation of positive markers was used categorical scores that determined the cutoff value in the percentage of stained tumor cells. Tissue expression of the proteins were correlated with the variables of degree of cell differentiation, staging, disease-free, recurrence, survival and specific mortality. We employed the Fisher exact test (Agresti, 1990) to study the association between tumor grade and TS, Cox-2, EGFR, MSH1, MSH6 and p53, and tumor staging correlated with TS, Cox-2, EGFR, MSH1, MSH6 and p53. Estimation of Kaplan-Meier (Collett, 2003), Log-rank test (Collett, 2003) and adjusting the Cox regression model (Cox, 1972) to investigate the behavior of the overall survival of patients (months) according to TS, COX-2, EGFR, MSH6, MLH1 and p53 and disease-free interval of subjects (months), according to TS, COX-2, EGFR, MSH6, MLH1 and p53. Results: The degree of tumor differentiation of individuals is not associated with TS (p = 0.138), COX-2 (p = 0.428), EGFR (p = 0.103), MSH6 (p = 0.876), MLH1 (p = 0.792) and p53 (p = 0.884). The staging is not associated with TS (p = 0.817), COX-2 (p = 0.842), EGFR (p = 0.344), MSH6 (p = 0.923) and p53 (p = 0.666). The same behavior was not observed for MLH1 (p = 0.021) in which the group of patients with stage III or IV is a higher percentage of MLH1 negative (27.4%) than in the group of patients with stage 0, I, or II (2.2%). The survival time of individuals is not related to TS (p = 0.480), COX-2 (p = 0.998), EGFR (p = 0.600), MSH6 (p = 0.318), MLH1 (p = 0.798) and p53 (p = 0.695). The disease-free interval of subjects is not related to TS (p = 0.356), COX-2 (p = 0.885), EGFR (p = 0.786), MSH6 (p = 0.178), MLH1 (p = 0.691) and p53 (p = 0.441). Conclusion: There was no correlation of the association between the degree of tumor differentiation, staging, survival time and disease-free interval with markers TS, p53, COX2, EGFR, MSH6. In advanced cases of RCC with stage III and IV, there was a higher percentage of MLH1 negative.
- ItemAcesso aberto (Open Access)Traditional biomarkers in narcolepsy: experience of a Brazilian sleep centre(Academia Brasileira de Neurologia - ABNEURO, 2010-10-01) Coelho, Fernando Morgadinho Santos [UNIFESP]; Pradella-Hallinan, Márcia Lurdes de Cássia [UNIFESP]; Pedrazzoli, Mario [UNIFESP]; Soares, Carlos Augusto Senne; Fernandes, Gustavo Bruniera Peres; Gonçalves, André Leite; Tufik, Sergio [UNIFESP]; Bittencourt, Lia Rita Azeredo [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Israelita Albert Einstein HospitalThis study was thought to characterized clinical and laboratory findings of a narcoleptic patients in an out patients unit at São Paulo, Brazil. METHOD: 28 patients underwent polysomnographic recordings (PSG) and Multiple Sleep Latency Test (MSLT) were analyzed according to standard criteria. The analysis of HLADQB1*0602 allele was performed by PCR. The Hypocretin-1 in cerebral spinal fluid (CSF) was measured using radioimmunoassay. Patients were divided in two groups according Hypocretin-1 level: Normal (N) - Hypocretin-1 higher than 110pg/ml and Lower (L) Hypocretin-1 lower than 110 pg/ml. RESULTS: Only 4 patients of the N group had cataplexy when compared with 14 members of the L group (p=0.0002). DISCUSSION: This results were comparable with other authors, confirming the utility of using specific biomarkers (HLA-DQB1*0602 allele and Hypocretin-1 CSF level) in narcolepsy with cataplexy. However, the HLADQB1*0602 allele and Hypocretin-1 level are insufficient to diagnose of narcolepsy without cataplexy.